HOME >> MEDICINE >> NEWS
Yale prostate cancer study shows newer implant therapy has fewer side-effects, could lead to better treatment outcomes

New Haven, Conn. -- A Yale study of complication rates from two radiation implant therapies for prostate cancer shows that the newer therapy, Palladium-103, has fewer long-term side effects than Iodine-125, an older, more commonly prescribed therapy.

"While both implants were extraordinarily successful at preventing major long-term complications, Palladium-103 was superior to Iodine-125 in preventing moderate long-term complications by 13 percent," said Richard Peschel, M.D., professor of therapeutic radiology at Yale School of Medicine. "Our study is the first to compare prostate cancer implant therapies, and the results could lead to improved outcomes for patients."

In the seven-year study, Peschel and his team also found that the minimum dose for Palladium-103 could be increased without increasing side effects. This increased dose has the potential for improving cure rates, Peschel says.

Published in the Oct. 29 issue of Radiation Oncology Investigations: Clinical and Basic Research, the findings are significant for men facing a treatment decision for prostate cancer.

When diagnosed with prostate cancer, most men are presented with two treatment options: radical surgery and implant therapy, which involves placing 75 to 100 small radioactive seeds throughout the prostate using a one-time, minimally invasive procedure. Implant therapy is an increasingly popular choice because it is a cheaper, simpler out-patient procedure that involves far less recovery time, a lower complication rate and cure rates that are equivalent to radical surgery.

For 10 to 15 years, Iodine-125 was the most frequently prescribed implant treatment, but newer therapies have emerged, including Palladium-103. Prostate cancer implant programs using either Iodine-125 or Palladium-103 radioactive seeds have been extremely successful in treating early prostate cancer. About 30,000 prostate implants will be performed in the United States in the year 2000.

The resear
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
28-Oct-1999


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Cultural and social factors influence prostate cancer treatment
3. Earlier use of prostate cancer vaccines urged by Hopkins scientists
4. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
5. Men more likely to get screened for prostate cancer than colon cancer, U-M study finds
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Obesity may affect accuracy of prostate screening
8. More precise radiation therapy lets prostate cancer patients avoid erectile dysfunction
9. Combining hormones with external, internal radiation helps high risk prostate cancer patients
10. Silent risk of osteoporosis in men with prostate cancer
11. NIH launches new study to compare prostate surgery and drugs

Post Your Comments:
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... 2014 Parker Waichman LLP, a personal injury ... that the heroes of 9/11 are never forgotten, comments that ... important deadline. According to a VCF message dated ... cancer on or before October 12, 2012 must file a ... and others who were allegedly injured by the toxic dust ...
(Date:7/28/2014)... Salt Lake City, Utah (PRWEB) July 28, 2014 ... supplements, protein powders and drinks, announced that it will ... protein drink line of products this summer. The additional ... combined with clean pure taste-free protein , Inspire Pomegranate ... Inspire Vanilla - flavor of soft-serve vanilla cone , ...
(Date:7/28/2014)... July 28, 2014 Mirena IUD lawsuits ... device caused some users to suffer serious injuries after ... uterus continue to mount in U.S. courts, Bernstein Liebhard ... issued last month in New Jersey, at least 924 ... multicounty litigation underway in Bergen County Superior Court. Some ...
(Date:7/28/2014)... Tenn. (PRWEB) July 28, 2014 St. ... 15 recipients of the Secretary of Defense Employer Support Freedom ... (ESGR) of the Department of Defense. The award is the ... their exceptional support of employees who serve in the National ... serve in the military for their contributions to the St. ...
Breaking Medicine News(10 mins):Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 4Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3
(Date:7/28/2014)... , July 28, 2014  Serco Inc., a ... the Company has been awarded a re-compete contract ... (NEMSCOM) and its Deployable Medical Systems.  Serco will ... personnel to provide world-class healthcare to meet warfighter ... across the globe. The five year contract has ...
(Date:7/28/2014)... , July 28, 2014  Array BioPharma Inc. ... for the fourth quarter and full year ... call to discuss those results on Tuesday, ... Officer and Michael Carruthers , Chief ... InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) ...
(Date:7/28/2014)... HONG KONG , July 28, 2014  Syneron ... global aesthetic device company, announced today that its new ... tattoos of all types and colors and pigmented lesions ... innovative dual wavelength device, with 532nm and 1064nm wavelengths, ... to the skin using pulses which are trillionths of ...
Breaking Medicine Technology:Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
Cached News: